Although the effect of parthenolide as an inhibitor of NF-κB activity has been reported previously in several cancers, its significance, detailed mechanism as B-Raf inhibitor for NSCLC has not yet been investigated [23, 24]. Here, BRAF is linked to non-small cell lung carcinoma.